US IPO Pipeline SEC S-1 Filings — June 26, 2026

Pro forma net income of $25.8M (basic EPS $3.52) for FY2025, up 8.4% from HBI standalone $23.8M (EPS $3.44), reflecting earnings accretion of $0.08/share from the merger with FBI, despite incurring $3.8M in merger costs

Company acquired 9,800 ASIC miners valued at $660.3M, pivoting into digital asset mining, but Dogecoin trades at $0.085—34.6%-43.3% below breakeven of $0.13-$0.15; mining at a loss with every coin mined, cash burn accelerates, strong short thesis

Revenue and cash flow trends negative; filing registration for up to 15.7M units at $0.6364 to fund new pivots into musical copyrights and RWA tokenization—dilution of ~100% of current shares at high risk of failure; management pledging no pre-filing insider buying

Phase IIa trial for Parkinson's Disease received final IND approval (Nov 2025), expected to start Q2 2026 (current), results anticipated 12 months later (Q2 2027)—catalyst for potential transformative upside if positive, but auditor has going concern opinion [NEUTRAL/BULLISH]

SPAC raising $250M at $10/unit targeting mineral resources; 13 non-binding institutional investors expressed interest for up to 11.35M units (45.4% of offering)—strong institutional validation but non-binding and no target selected; warrants at $11.50 provide downside protection premium

Lock-up shares from BSG merger cannot be sold unless VWAP > $16.00 over 10 trading days, monthly cap of 1/18th of shares, $35 trigger for unrestricted sale—insider selling mechanism protects shareholders from immediate dump, but current price implied by miner cost may be far lower

Pro forma total assets $2.23B (up from $1.86B HBI standalone, +19.9%), total deposits $1.86B, net loans $1.71B—scale creates cost synergies and competitive regional positioning, but $3.8M merger costs will depress near-term earnings by ~$0.52/share

No insider buying or selling reported in S-1; management implicitly underwhelmed by their own offering—zero skin in the game for a company pivoting to speculative assets

Launched Nugevia consumer supplement DTC in Q4 2025 with no meaningful revenue yet; SEPA with Yorkville registers 16M shares for resale—dilution overhang but provides capital access; net losses since inception, no product sales revenue

Pro forma net loan portfolio $1.71B with allowance for credit losses of $22.8M (1.33% coverage)—strong asset quality in a potentially easing credit environment, supporting future earnings stability

Dogecoin at $0.085 vs. required $0.13-$0.15, a -34.6% to -43.3% shortfall; mining at 9,800 ASICs requires variable costs of $0.088/kWh (hosting power) and ~$0.05/kWh other—cash burn rate of ~$10M+ annually based on 1.5kWh/ASIC at 90% uptime; miner fleet could become stranded if DOGE does not rally

Accumulated deficit of $113.9M as of March 31, 2026, with no revenue from legacy biopharma operations; Big Dig transformation to digital mining uses existing cash and likely debt—liquidity risk extreme; no insider buying detected

Legacy recruitment business 'faces significant headwinds', company has history of operating losses; pivoting to musical copyrights and RWA tokenization—sectors with high failure rates for small caps; no positive period-over-period revenue or margin trend disclosed

Auditor expressed substantial doubt for two consecutive fiscal years (2024, 2025); no product revenue, only losses; SEPA registration for 16M shares will potentially dilute current holders heavily—if Yorkville sells aggressively, stock could trade below warrants' exercise price

No business combination target selected; 'may pursue any industry' despite mineral resources focus—overly broad mandate could lead to suboptimal deal; non-binding LOIs from 13 institutional investors do not guarantee participation

Pro forma costs include $3.8M in estimated merger costs ($2.2M additional non-interest expense for FY2025); integration of two banks with different cultures and systems may face operational hurdles; basic EPS accretion of only $0.08/share (2.3% uplift) minimal relative to deal size and risk

None of the four IPO/survival filings show any insider buying in the 6 months prior; management teams not putting personal capital at risk in dilutive or transformative raises—weak alignment with retail investors

No mention of regulatory compliance for crypto mining in the filing; if US states or SEC impose stricter energy or registration requirements, mining operations could be disrupted, further impairing breakeven

Offering up to 15.7M units at $0.6364; current shares outstanding likely similar or lower—dilution >100% at assumed price, severely diluting existing holders for uncertain pivots

Phase IIa Parkinson's trial (expected Q2 2026 start, results Q2 2027) may fail to meet endpoints; no other pipeline products; if JOTROL fails, company has no value driver—share price could go to zero

Pro forma EPS $3.52 vs. $3.44 standalone, plus $1.86B deposits provide funding advantages; if merger closes successfully and cost synergies exceed $3.8M estimate, upside EPS could exceed 10%—trading at 0.8x pro forma tangible book (est.) vs. regional bank index 1.1x

Phase IIa Parkinson's data expected Q2 2027, with final IND approval secured and trial starting now; if positive, JOTROL could address large CNS market with no current treatment—multiple expansion potential; current market cap likely undervalued vs. pipeline peers; warrants cheap for out-of-money call optionality

Mineral resources SPAC launching as central banks and governments push for critical minerals (copper, lithium, rare earths); $250M trust offers 2-3x leverage on a merger with a private operator; warrants at $11.50 provide optionality if target selected in next 18-24 months

If Dogecoin unexpectedly rallies >$0.13 (e.g., due to regulatory clarity, memecoin season, or payment adoption), miner fleet profitable immediately; 9,800 ASICs at $660.3M valuation imply ~$67,000 per miner; with breach even close, option-like upside on volatile DOGE; small current market cap could multiply 3-5x on DOGE to $0.15

Current stock likely trading at distressed levels; if RWA tokenization or music copyright generates first revenue in 12 months, speculative upside large; pre-funded warrants offer downpayment-like risk; small allocation for high-risk/high-reward bounce if pivot gains traction

$490.4M non-interest-bearing deposits (26.4% of total) is strong for a $2.23B regional bank; in a high-rate environment, this provides low-cost funding advantage vs. peers—could support NIM expansion of 10-15 bps over next 12 months

3 of 5 filings (Professional Diversity Network, Jupiter Neurosciences, Coeptis) represent companies with failing legacy models pivoting to entirely new, high-risk businesses (music copyrights, supplements, crypto mining). These companies are using cheap equity or dilution to fund desperation pivots, indicating weak IPO pipeline quality [Theme]

Across all 4 non-Hawthorn filings, zero insider purchases or sales reported in a 6-month window—management teams exhibit no personal financial commitment to their companies' recovery, a red flag for minority investor alignment [Theme]

2 of 5 filings (Coeptis and Jupiter) explicitly disclose auditor going concern opinions, and both are raising capital under severe deficit conditions. Only Hawthorn Bancshares shows positive financial stability (pro forma earnings accretion) [Theme]

AMR Resources marks 1 SPAC IPO in a market that had almost zero SPAC activity in 2025; targeting mineral resources aligns with critical minerals demand, suggesting a niche recovery for blank-check vehicles [Theme]

None of the 5 filings represent traditional operating companies with sustained profitability, positive cash flow, or organic growth. The pipeline consists solely of distressed pivots, a SPAC, and a bank merger—no quality new issuances, signaling a continued low point in IPO quality [Theme]

Monitor Dogecoin price; if DOGE crosses $0.13, breakeven threshold triggered with massive upside potential; also watch for any additional equity raises to fund power costs; no date, but weekly crypto price action is key

Phase IIa Parkinson's trial start (Q2 2026, i.e., now) and results expected Q2 2027; watch for any enrollment updates, FDA communications, or adverse events—catalyst could move stock 200-500% if positive

Merger completion date and integration milestones; S-4 filing is pending, but joint shareholder meeting likely in Q3 2026; watch for regulatory approvals from banking authorities

IPO pricing and initial trading (unit likely begins trading on Nasdaq within 2 weeks); watch for first target announcement or any binding LOI—could be announced within 12 months, providing first catalyst

Effectiveness date of S-1 and actual offering pricing; if offering completes, track use of proceeds in musical copyrights vs. RWA—any news of first asset acquisition would signal pivot materialization

Any US regulation on cryptocurrency mining could impact Coeptis; also, DOGE's classification as a commodity vs. security may affect miner operations—monitor SEC statements

Insider trading filings post-offering; if management buys shares after the dilution (e.g., Coeptis management buying), it would signal confidence; if no buying, reinforces bearish thesis